Clinical Trials
75 trialsThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
EvoPAR-PR02
AstraZeneca
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
TRAP
Royal Marsden NHS Foundation Trust
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
rechARge
Celgene
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Arvinas Inc.
DIVINE
Mayo Clinic
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
TRIPLE-SWITCH
Canadian Cancer Trials Group
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
VA STARPORT
VA Office of Research and Development
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
CELLO-1
Ipsen
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
AcTFirst
Novartis
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
SPLASH
Eli Lilly and Company
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
University of California, San Francisco
Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
SMED Clinical Research
CONTACT-02
Exelixis
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Abiraterone Acetate for Castrate Resistant Prostate Cancer
Massachusetts General Hospital
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
University of Chicago
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Curium US LLC
CYCLONE 3
Eli Lilly and Company
IPATential150
Hoffmann-La Roche
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Thomas Jefferson University
ERA 223
Bayer
PK and Dose Escalation and Expansion Study of DST-2970
DisperSol Technologies, LLC
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Pellficure Pharmaceuticals, Inc
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Sorrento Therapeutics, Inc.
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
RASTOM
First Hospital of China Medical University
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca